Barclays Reiterates an 'Overweight' on Two Harbors Investment (TWO); Management Meetings Reinforce Bullish View
Get Alerts TWO Hot Sheet
Price: $12.03 +0.17%
Rating Summary:
4 Buy, 20 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 10 | Down: 12 | New: 19
Rating Summary:
4 Buy, 20 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 10 | Down: 12 | New: 19
Join SI Premium – FREE
Barclays reiterates an 'Overweight' on Two Harbors Investment (NYSE: TWO) price target of $11.00.
Barclays analyst says, "We hosted meetings with Co-CIO Bill Roth and Head of IR Christine Battist on Wednesday on the heels of recent market volatility in the sector that we believe has left the shares of mortgage REITs like TWO mispriced. The takeaways of the meetings reinforced our view that the stock is poised to outperform in both the short and long term. With the stock trading at only 0.91x book and 18% dividend yield, we believe it represents an attractive total return opportunity and reiterate our rating."
For more ratings news on Two Harbors Investment click here and for the rating history of Two Harbors Investment click here.
Shares of Two Harbors Investment closed at $8.88 yesterday.
Barclays analyst says, "We hosted meetings with Co-CIO Bill Roth and Head of IR Christine Battist on Wednesday on the heels of recent market volatility in the sector that we believe has left the shares of mortgage REITs like TWO mispriced. The takeaways of the meetings reinforced our view that the stock is poised to outperform in both the short and long term. With the stock trading at only 0.91x book and 18% dividend yield, we believe it represents an attractive total return opportunity and reiterate our rating."
For more ratings news on Two Harbors Investment click here and for the rating history of Two Harbors Investment click here.
Shares of Two Harbors Investment closed at $8.88 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Hims and Hers (HIMS) PT Lowered to $35 at Barclays
- UBS Reiterates Buy Rating on Bristol-Myers Squibb Co. (BMY)
- BofA Securities Starts ProQR Therapeutics N.V. (PRQR) at Buy
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
Barclays, DividendSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share